Amylin Pharmaceuticals LLC

Amylin Pharmaceuticals — Merger or Acquisition (November 2011)

29 slides from Amylin Pharmaceuticals's merger presentation, Nov 8, 2011

  1. Slide 1: Amylin Secures Control of Global Rights to Exenatide

    Amylin Pharmaceuticals, Inc. Amylin Secures Control of Global Rights to Exenatide November 8, 2011

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA, SYMLIN, or BYDUREON and the

  3. Slide 3: Amylin Secures Global Rights to Exenatide

    Amylin Secures Global Rights to Exenatide Agreement Summary Strategic Rationale Operational Strategy Financial Terms ne

  4. Slide 4: Agreement Summary

    Agreement Summary Strategic Rationale Operational Strategy Financial Terms Amylin Secures Global Rights to Exenatide

  5. Slide 5: Amylin Secures Global Rights to Exenatide

    Amylin Secures Global Rights to Exenatide Terms Consideration Upfront Payment Revenue Sharing Obligation (RSO) Total Consideration Terms $250mm $1,200mm) $1.45bn + Amylin secures global exenatide rights for $1.45bn gross « U.S. operations will transfer November 30%, 2011 + Outside U.S. operations wi

  6. Slide 6: Key Features of the Agreement

    Key Features of the Agreement Amylin gains full operational control of exenatide franchise Staged consideration of $1.45bn > $250mm cash upfront, payable from existing cash balances > $1.2bn face amount of RSO, paid ratably with sales or faster (no prepayment penalty) Accretive to Amylin’s cash flow

  7. Slide 7: Strategic Rationale

    Agreement Summary Strategic Rationale Operational Strategy Financial Terms Amylin Secures Global Rights to Exenatide

  8. Slide 8: Compelling Strategic Rationale to Gain Global Control of a Diabetes Franchise

    Compelling Strategic Rationale to Gain Global Control of a Diabetes Franchise with Proven Medical and Economic Value Global Rights to Assets with Blockbuster Potential } Operational and Strategic Control Ensure Successful Execution Prioritizes Exenatide Franchise Across Entire Field Force ] Efficien

  9. Slide 9: Pioneering Innovative Therapies to Target Unmet Needs

    ° Pioneering Innovative Therapies to Target Unmet Needs Across the Spectrum of Diabetes Molecule Metabolic Disease Sales-Force Focus 15 Weekly “(Exenatide) > Diabetes Therapy | _BYOUREON 4stin Class BYETTA® (Exenatide) > 4%tin Class SYMLIN’ (Pr: Type 1 & Type 2 diabetes Specialty | 1*in Class 2D Rar

  10. Slide 10: The Exenatide Franchise Targets an Expanding Commercial Opportunity

    10 The Exenatide Franchise Targets an Expanding Commercial Opportunity and Enables Amylin to Shape the GLP-1 Market GLP-1 market continues to expand } BYETTA - daily dosing (Sin milions) 5% GLP-4 Class: $1,750 + Approaching $2B in worldwide sales +% + ~5% of branded U.S. type 2 diabetes medications

  11. Slide 11: BYETTA + Insulin Glargine Indication Broadens Label for BYETTA

    BYETTA + Insulin Glargine Indication Broadens Label for BYETTA and Creates a Well-Defined Position in the Market Rapid Acting Insulins are one of the largest and BYETTA + insulin glargine expands GLP-1 fastest growing insulin segments opportunity + BYETTA is an ideal partner to insulin glargine > Fi

  12. Slide 12: Strategically Managing Product Lifecycles

    Strategically Managing Product Lifecycles Molecule Frequency Reconstitute BYETTA 2X Daily No Single-chamber pen BYDUREON cDKt Yes Exenatide BYDUREON pen Weekly Dual-chamber pen Weekly Suspension No Single-chamber pen Monthly Suspension Monthly ; oe ‘SYMLIN SYMLIN U.S. Diabetes Market Yn > (72) TH) I

  13. Slide 13: Operational Strategy

    3 Amylin Secures Global Rights to Exenatide Agreement Summary Strategic Rationale Operational Strategy Financial Terms

  14. Slide 14: Operational Control of Exenatide Increases Efficiency and Flexibility

    “ Operational Control of Exenatide Increases Efficiency and Flexibility Allowing Amylin to Clearly Define the Path Forward Exenatide U.S. Operational Strateqy » On November 30, 2011, the Exenatide Commercial Unit will take control of the U.S. BYETTA franchise > ExenatideOne dissolves and U.S. BYETTA

  15. Slide 15: Creation of Focused Commercial Units Maximizes the Value of Marketed Brands

    1 Creation of Focused Commercial Units Maximizes the Value of Marketed Brands Amylin U.S. Operational Strategy — Post BYDUREON Approval * The Exenatide Commercial Unit will focus on the commercialization of BYETTA, and if approved, BYDUREON and exenatide suspension products » The Endocrine Commercia

  16. Slide 16: Maximizing the Value of the U.S. BYDUREON Launch

    Maximizing the Value of the U.S. BYDUREON Launch and the Exenatide Franchise with a Focused Sales Force BYDUREON Launch: Projected Sales-Force Alignment with LLY Partnership BYDUREON 1 Position » Variable detail position for BYDUREON in Lilly sleeves BYETTA 2 Position 325 Amylin reps * No proactive

  17. Slide 17: Amylin Will Seek A New Partner for OUS Commercialization

    7 Amylin Will Seek A New Partner for OUS Commercialization, while Key Operational Activities Remain on Track Exenatide OUS Commercial Strategy ~ Lilly continues to commercialize BYETTA and BYDUREON in outside U.S. markets until transitioned to Amylin but not later than December 31, 2013 > Amylin is

  18. Slide 18: Multiple Value Drivers Through 2013

    Multiple Value Drivers Through 2013 BYDUREON BYETTA Exenatide Suspension Metreleptin Exenatide Rights Agreement cuted

  19. Slide 19: Financial Terms

    w Amylin Secures Global Rights to Exenatide Agreement Summary Strategic Rationale Operational Strategy Financial Terms

  20. Slide 20: Summary of Terms

    20 Summary of Terms Terms Consideration Upfront Payment $250mm Revenue Sharing Obligation $1,200mm( Total Consideration $1.45bn Terms Description RSO Payments to Eli Lilly RSO Accretion Rate RSO Guarantee OUS Loss Protection Eli Lilly Loan Milestone Payment 15% of WW exenatide net revenue until tota

  21. Slide 21: Exenatide Global Rights Agreement is Structured to Retain Financial Flexibility

    21 Exenatide Global Rights Agreement is Structured to Retain Financial Flexibility Near-term cash balance is reduced... The $250mm upfront payment reduces our 32011 cash balance to $210mm on a pro forma basis RSO facility designed with a favorable payback mechanism that ties cash outlay in any perio

  22. Slide 22: Consideration Structure Maximizes Financial Flexibility

    Consideration Structure Maximizes Financial Flexibility Consideration Value | | RSO Summary « Creates risk symmetry between revenue ramp and (Sinmitons) Uptione: repayment obligations Payment $250 > Higher revenues result in a more rapid pay down + Interest, accrued at a rate of 9.5% per annum, is a

  23. Slide 23: Securing Global Rights to Exenatide Results in Significantly Improved Financial Leverage

    2 oO) 2 Securing Global Rights to Exenatide Results in Significantly Improved Financial Leverage Structure BYETTA/B' IREON Before BYETTA/BYDUREON After Collaborative Profit 50% of Gross Profit 100% of Gross Profit with 15% net Share sales revenue sharing obligation US. 50% of U.S. expenses Expenses

  24. Slide 24: Agreement Results in Significantly Improved Gross Profit

    Agreement Results in Significantly Improved Gross Profit Exenatide U.S. Product Contribution: Example for illustrative purposes only Product sales 1000 1000 Gross Profit (80% blended exenatide margin) 800 800 Profit Sharing (50% of exenatide gross profit) (400) - RSO (15% of net exenatide sales) - (

  25. Slide 25: Blended Exenatide Gross Margins Remain Strong Through the Planned BYDUREON Launch

    Blended Exenatide Gross Margins Remain Strong Through the Planned BYDUREON Launch Targeting blended gross margins for exenatide of 75-80% + Gross margin variability expected over the next few years due to the following factors. > Ramp in BYDUREON margins as fixed manufacturing costs will be spread o

  26. Slide 26: Improved Gross-Profit Economics in 2012 Fund the Majority of Incremental Cash Operating Expenses

    Improved Gross-Profit Economics in 2012 Fund the Majority of Incremental Cash Operating Expenses Revenue" » Exenatide franchise drives GLP-1 class growth » Agreement precipitates elimination of U.S. launch milestone Gross Margins" » Expect combined gross margins in 2012 to be approximately 80%” » Ca

  27. Slide 27: Amylin is Positioned to Deliver Greater Shareholder Value

    Amylin is Positioned to Deliver Greater Shareholder Value Current Exenatide Economics VA Interim Exenatide Economics” Va Post-RSO” Exenatide Economics" > UsExenaide 0% ofUS OUSExenatde _ Exanatide USExenatde 100% ofUS 16% Net Increased _ Exanatide UsExenatde 100% of US Increased Exanatide “atteof Ev

  28. Slide 28: A Value-Creating Agreement that Enhances Existing Operating Leverage

    28 A Value-Creating Agreement that Enhances Existing Operating Leverage and Drives Bottom-Line Growth * Significantly increased exposure to exenatide gross profits > 15% revenue sharing obligation vs 50% gross profit share * Favorable payback mechanism as revenue sharing payments are dependent on le

  29. Slide 29: Amylin: Committed to Changing the Way Diabetes is Treated

    Amylin: Committed to Changing the Way Diabetes is Treated » As anewera begins at Amylin, our commitment to delivering maximum value to patients, payers and physicians is unwavering » Leveraging first-in-class molecules, a metabolic-disease infrastructure and a targeted sales approach enables Amylin

Amylin Pharmaceuticals — Merger or Acquisition (November 2011) on 6ix